SILO vs XWEL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
SILO exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company is currently pre-revenue or stagnant (0% YoY growth) with an unsustainable operating margin of -4363.27%. While a high current ratio of 11.36 suggests a temporary cash runway, the long-term trajectory is severely negative with a 5-year price decline of 96%. The recent 1-month price spike appears to be speculative volatility rather than a fundamental turnaround.
XWEL exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -1.04, indicating negative shareholder equity. The company is facing a liquidity crisis with a Current Ratio of 0.46 and a Quick Ratio of 0.33, suggesting it cannot meet its short-term obligations. While there has been a speculative 1-year price recovery and recent EPS 'beats,' these are relative to deeply negative expectations and do not offset the fundamental insolvency risks. The combination of declining revenue (-4.20% YoY) and negative margins makes the current valuation unsustainable.
Compare Another Pair
Related Comparisons
SILO vs XWEL: Head-to-Head Comparison
This page compares Silo Pharma, Inc. (SILO) and XWELL, Inc. (XWEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.